Join us at our online conference on Stem Cells and Treatment of Parkinson’s Disease on January 29, 2021 at 2:30 pm (duration: 1 hour – available in French only)
An innovative approach to the fight against Parkinson’s disease
In this online conference, Dr. Janelle Drouin-Ouellet will explain in detail the different therapeutic options related to stem cells.
Her groundbreaking research project involves reprogramming neurons from skin samples of people suffering from Parkinson’s disease.
“The advantage of using skin cells is that they are easily accessible and they multiply, which allows us to build up a stock of cells with the same genetic material as the patients’ brains,” said Drouin-Ouellet.
Janelle Drouin-Ouellet’s innovative approach is in line with the trend towards personalized medicine, which would make it possible to study the response of neurons to a treatment and thus find the best therapeutic solution for each patient using a simple skin or urine sample.
Dr. Janelle Drouin-Ouellet, neurobiologist and neural reprogramming researcher in Montreal.
Janelle Drouin-Ouellet obtained her Ph.D. in Neurobiology at Université Laval and subsequently completed a first postdoctoral fellowship at the University of Cambridge, UK. She continued her postdoctoral work in the laboratory of Professor Malin Parmar at the University of Lund, Sweden, where she developed a simple and effective approach for direct neuronal reprogramming of skin fibroblasts of patients with various neurodegenerative diseases. She was recently appointed Assistant Professor at the Faculty of Pharmacy of the Université de Montréal.
(source: Faculty of Pharmacy, Université de Montréal)
Her approach to Parkinson’s disease research recently got Janelle Drouin-Ouellet named to the Brain Canada Foundation’s list of 20 ‘Azrieli Future Leaders in Canadian Brain Research.
Through its funding, Parkinson Quebec is supporting Dr. Drouin-Ouellet’s research for the project:
Development of a model by direct cellular reprogramming of patient cells to study the neuroinflammatory component of Parkinson’s disease in order to identify new pharmacological targets.
We hope you will be able to join us for this conference!